Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.
Animals
Biomarkers
/ blood
Blood Glucose
/ drug effects
Diabetes Mellitus, Type 1
/ blood
Diabetes Mellitus, Type 2
/ blood
Dipeptidyl-Peptidase IV Inhibitors
/ therapeutic use
Drug Therapy, Combination
Glycosides
/ adverse effects
Humans
Kidney
/ drug effects
Sodium-Glucose Transporter 1
/ antagonists & inhibitors
Sodium-Glucose Transporter 2
/ drug effects
Sodium-Glucose Transporter 2 Inhibitors
/ adverse effects
Treatment Outcome
Diabetes
Hypoglycemic therapy
SGLT2 inhibitors
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
28 02 2019
28 02 2019
Historique:
received:
23
12
2018
accepted:
19
02
2019
entrez:
2
3
2019
pubmed:
2
3
2019
medline:
24
4
2019
Statut:
epublish
Résumé
Sotagliflozin is a dual sodium-glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D). Sotagliflozin inhibits renal sodium-glucose co-transporter 2 (determining significant excretion of glucose in the urine, in the same way as other, already available SGLT-2 selective inhibitors) and intestinal SGLT-1, delaying glucose absorption and therefore reducing post prandial glucose. Well-designed clinical trials, have shown that sotagliflozin (as monotherapy or add-on therapy to other anti-hyperglycemic agents) improves glycated hemoglobin in adults with T2D, with beneficial effects on bodyweight and blood pressure. Similar results have been obtained in adults with T1D treated with either continuous subcutaneous insulin infusion or multiple daily insulin injections, even after insulin optimization. A still ongoing phase 3 study is currently evaluating the effect of sotagliflozin on cardiovascular outcomes (ClinicalTrials.gov NCT03315143). In this review we illustrate the advantages and disadvantages of dual SGLT 2/1 inhibition, in order to better characterize and investigate its mechanisms of action and potentialities.
Identifiants
pubmed: 30819210
doi: 10.1186/s12933-019-0828-y
pii: 10.1186/s12933-019-0828-y
pmc: PMC6393994
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
Dipeptidyl-Peptidase IV Inhibitors
0
Glycosides
0
SLC5A1 protein, human
0
SLC5A2 protein, human
0
Sodium-Glucose Transporter 1
0
Sodium-Glucose Transporter 2
0
Sodium-Glucose Transporter 2 Inhibitors
0
(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol
6B4ZBS263Y
Banques de données
ClinicalTrials.gov
['NCT03315143']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
20Références
Lancet. 2019 Jan 5;393(10166):31-39
pubmed: 30424892
Diabetes Care. 2014 May;37(5):1480-3
pubmed: 24595630
Cardiovasc Diabetol. 2013 May 04;12:73
pubmed: 23642288
Circulation. 2018 Jan 23;137(4):323-334
pubmed: 29133604
Clin Pharmacol Ther. 2012 Aug;92(2):158-69
pubmed: 22739142
Diabetes Care. 2008 Aug;31(8):1473-8
pubmed: 18540046
J Pharmacol Exp Ther. 2013 May;345(2):250-9
pubmed: 23487174
Diabetes Metab Res Rev. 2005 Jan-Feb;21(1):31-8
pubmed: 15624123
N Engl J Med. 1993 Sep 30;329(14):977-86
pubmed: 8366922
Cardiovasc Diabetol. 2016 Jul 15;15:97
pubmed: 27422625
N Engl J Med. 2017 Dec 14;377(24):2337-2348
pubmed: 28899222
BMJ Open. 2017 Oct 16;7(10):e018097
pubmed: 29042392
PLoS One. 2014 Jul 02;9(7):e100778
pubmed: 24988476
Endocr J. 2017 Sep 30;64(9):923-931
pubmed: 28824041
Drugs. 2015 Jan;75(1):33-59
pubmed: 25488697
Diabetes. 2014 Mar;63(3):994-1007
pubmed: 24215793
Lancet Diabetes Endocrinol. 2014 May;2(5):369-84
pubmed: 24795251
Diabetes Metab. 2017 Dec;43(6):512-520
pubmed: 28499695
Am J Physiol Renal Physiol. 2014 Jan;306(2):F188-93
pubmed: 24226519
Diabetes Care. 2017 Jan;40(1):54-62
pubmed: 27999002
Lab Invest. 2016 Jan;96(1):98-111
pubmed: 26552046
Diab Vasc Dis Res. 2015 Mar;12(2):90-100
pubmed: 25589482
Lancet Diabetes Endocrinol. 2016 Dec;4(12):1004-1016
pubmed: 27651331
Nat Med. 2015 May;21(5):512-7
pubmed: 25894829
AAPS J. 2011 Dec;13(4):576-84
pubmed: 21870203
Circulation. 2017 Jul 18;136(3):249-259
pubmed: 28522450
J Clin Invest. 2014 Feb;124(2):499-508
pubmed: 24463454
PLoS One. 2014 Nov 17;9(11):e112394
pubmed: 25402275
Am J Physiol Endocrinol Metab. 2008 Nov;295(5):E1160-6
pubmed: 18796545
J Exp Biol. 1994 Nov;196:197-212
pubmed: 7823022
Diabet Med. 2007 Jun;24(6):600-6
pubmed: 17381499
JPEN J Parenter Enteral Nutr. 2004 Sep-Oct;28(5):364-71
pubmed: 15449578
Diabetes Care. 2016 Feb;39(2):198-205
pubmed: 26285584
Diabetes. 2008 Jun;57(6):1723-9
pubmed: 18356408
Diabetes Care. 2015 Sep;38(9):1687-93
pubmed: 26078479
Diabetes Care. 2013 Aug;36(8):2154-61
pubmed: 23412078
J Pharmacol Exp Ther. 2017 Jul;362(1):85-97
pubmed: 28442582
Endocrinology. 2003 Jul;144(7):3244-50
pubmed: 12810581
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Am Heart J. 2018 Jun;200:83-89
pubmed: 29898853
J Am Coll Cardiol. 2018 Oct 9;72(15):1763-1773
pubmed: 30286918
J Diabetes Sci Technol. 2017 Jan;11(1):157-159
pubmed: 28264172
Pflugers Arch. 2015 Sep;467(9):1881-98
pubmed: 25304002
PLoS One. 2015 Jun 29;10(6):e0130605
pubmed: 26121582
BMJ Open. 2017 Aug 1;7(7):e016587
pubmed: 28765134
Diabetologia. 2015 Nov;58(11):2503-12
pubmed: 26224101
Physiol Rep. 2014 Jun 27;2(6):
pubmed: 24973332
Postgrad Med. 2017 May;129(4):409-420
pubmed: 28322073
Diabetes Obes Metab. 2011 Jul;13(7):669-72
pubmed: 21457428
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Lancet Diabetes Endocrinol. 2017 Nov;5(11):864-876
pubmed: 28919061
Physiol Rev. 2011 Apr;91(2):733-94
pubmed: 21527736
Lancet Diabetes Endocrinol. 2018 May;6(5):370-381
pubmed: 29483060
Diabetes Care. 2015 Mar;38(3):431-8
pubmed: 25216510
Nat Rev Drug Discov. 2010 Jul;9(7):551-9
pubmed: 20508640
Drug Des Devel Ther. 2017 Oct 03;11:2905-2919
pubmed: 29042751
Diabetologia. 2016 Aug;59(8):1645-54
pubmed: 27216492
Diabetes Care. 2016 Oct;39(10):1702-10
pubmed: 27506222
J Endocrinol. 2015 Mar;224(3):205-14
pubmed: 25486965
Eur J Heart Fail. 2010 Feb;12(2):106-13
pubmed: 20083620
Cardiovasc Diabetol. 2017 Apr 12;16(1):48
pubmed: 28403850
Cardiovasc Diabetol. 2018 Feb 19;17(1):30
pubmed: 29458368
Digestion. 1995;56(2):117-26
pubmed: 7750665
J Clin Invest. 1976 Jul;58(1):83-90
pubmed: 932211
Am J Physiol. 1956 Jan;184(1):91-6
pubmed: 13283096
Expert Opin Investig Drugs. 2013 Apr;22(4):463-86
pubmed: 23452053
Lancet Diabetes Endocrinol. 2017 Aug;5(8):597-609
pubmed: 28615149
Diabetes Metab Res Rev. 2000 Mar-Apr;16(2):125-32
pubmed: 10751752
J Clin Med Res. 2017 Sep;9(9):745-753
pubmed: 28811850
Diabetes Care. 2009 Apr;32(4):650-7
pubmed: 19114612
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Diabetes. 2008 Sep;57(9):2280-7
pubmed: 18519800
Cardiovasc Diabetol. 2015 Oct 17;14:142
pubmed: 26474563
Diabetes Obes Metab. 2018 Feb;20(2):370-377
pubmed: 28786557
Diabet Med. 2011 Oct;28(10):1176-81
pubmed: 21923696
Diabetes Care. 2015 Jul;38(7):1181-8
pubmed: 26049551
Diabetes. 2013 Oct;62(10):3324-8
pubmed: 24065789
Clin Ther. 2013 Mar;35(3):273-285.e7
pubmed: 23433601
Am J Physiol Endocrinol Metab. 2013 Jan 15;304(2):E117-30
pubmed: 23149623
Kidney Int. 2014 Apr;85(4):962-71
pubmed: 24067431
Nat Med. 2017 Jul;23(7):850-858
pubmed: 28530702
Diabetes Care. 2015 Dec;38(12):2258-65
pubmed: 26486192
Diabetes Obes Metab. 2015 Oct;17(10):928-35
pubmed: 26080652
Nat Med. 2005 Jan;11(1):90-4
pubmed: 15619630
Expert Opin Drug Metab Toxicol. 2016 Dec;12(12):1407-1417
pubmed: 27435042
Cardiovasc Diabetol. 2017 Oct 12;16(1):130
pubmed: 29025406
Diabetes Obes Metab. 2012 Jan;14(1):83-90
pubmed: 21985634
Biochem Biophys Res Commun. 2004 Feb 6;314(2):301-5
pubmed: 14733905
Biochem Biophys Res Commun. 2017 Oct 14;492(2):161-165
pubmed: 28803984
J Clin Endocrinol Metab. 2015 Aug;100(8):2849-52
pubmed: 26086329
Clin Drug Investig. 2014 Oct;34(10):731-42
pubmed: 25200141
Clin Ther. 2016 Oct;38(10):2265-2276
pubmed: 27692976
Diabetes Metab Syndr Obes. 2015 Feb 26;8:121-7
pubmed: 25759591
Pharmacol Res Perspect. 2015 Mar;3(2):e00129
pubmed: 26038705
Clin Ther. 2015 Jan 1;37(1):71-82.e12
pubmed: 25529979
Diab Vasc Dis Res. 2015 Mar;12(2):101-10
pubmed: 25690134
J Clin Endocrinol Metab. 2006 Mar;91(3):813-9
pubmed: 16352690
N Engl J Med. 2013 Jul 25;369(4):362-72
pubmed: 23883381
Diabetologia. 2008 Aug;51(8):1552-3
pubmed: 18528677
Diabetes Care. 2015 Mar;38(3):412-9
pubmed: 25271207
Endocr Pract. 2016 Jun;22(6):753-62
pubmed: 27082665